Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Acorda Therapeutics (ACOR) is now available.
Acorda Therapeutics, Inc. has initiated voluntary Chapter 11 proceedings and is working to sell its assets for $185 million to Merz Pharmaceuticals, LLC, subject to higher bids and court approval. Concurrently, the company has secured debtor-in-possession financing to maintain operations, with terms including a $60 million credit facility. These strategic moves aim to stabilize the company’s operations while they navigate through bankruptcy and restructuring efforts.
See more insights into ACOR stock on TipRanks’ Stock Analysis page.
